Objectives: Carbapenemases such as MBLs are spreading among Gram-negative bacterial pathogens. Infections due to these MDR bacteria constitute a major global health challenge. Therapeutic strategies against carbapenemase-producing bacteria include b-lactamase inhibitor combinations. [S,S]-ethylenediamine-N,N 0 -disuccinic acid (EDDS) is a chelator and potential inhibitor of MBLs. We investigated the activity of EDDS in combination with imipenem against MBL-producing bacteria in vitro as well as in vivo.
Introduction
Antibiotic resistance in bacterial pathogens constitutes one of the major threats regarding human health. [1] [2] [3] An alarming trend is the spread of carbapenemases among Gram-negative pathogens that can confer resistance to almost all b-lactams, including carbapenems. 4 Production of b-lactamases is the most common mechanism of resistance to b-lactam antibiotics in Gram-negative pathogens. 5 According to the Ambler classification, b-lactamases can be divided into two major groups, i.e. serine-b-lactamases (SBLs) and MBLs. MBLs have been further divided into subclasses B1-B3, the B1 subclass being relevant for Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. Whereas there are efficient inhibitors of SBLs available, i.e. clavulanic acid, tazobactam, sulbactam and avibactam, 6, 7 no clinically useful antagonist of MBL activity has yet been reported.
Hence, to overcome MBL-mediated resistance, a combination of a b-lactam and a b-lactamase inhibitor, which protects the b-lactam antibiotic from the activity of the MBL, is urgently needed. 6, 8 Zinc chelators are able to remove zinc ions from the active site of MBLs; hence, these compounds are discussed as therapeutic options concerning development of new MBL inhibitors. Potent zinc chelators, e.g. EDTA, N,N,N 0 ,N 0 -tetrakis(2-pyridylmethyl)ethylenediamine, di-(2-picolyl)amine and 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid, have been proved to restore carbapenem activity against MBL-producing bacteria. 9 Besides synthetic chelators, many microorganisms secrete metallo-chelating natural compounds such as siderophores and zincophores, providing an unexplored pool of potential MBL inhibitors. Recently, the fungal natural product aspergillomarasmine A, isolated from Aspergillus versicolor, showed good inhibitory activity against NDM-1 and VIM-2, in vitro and in vivo. 10 Consequently, we assumed that naturally produced zincophores with similar structures may show similar properties regarding MBL inhibition. [S,S]-ethylenediamine-N,N 0 -disuccinic acid (EDDS) is produced by a wide range of bacteria and is described as a zincophore, contributing to zinc uptake ( Figure 1 ).
11
This study was undertaken to evaluate the potential of EDDS to function as an MBL inhibitor and, in combination with imipenem, to confer activity against MBL-producing bacteria in vitro and in vivo.
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Materials and methods

Bacterial strains
Clinical isolates as well as bacterial mutants expressing various MBLs were used for antimicrobial susceptibility testing. For the generation of bacterial mutants, genes encoding NDM-1, IMP-1, VIM-1 and SIM-1 were amplified by conventional PCR using the primers shown in Table S1 (available as Supplementary data at JAC Online). Purified PCR amplicons were cloned into pCR-Blunt II-TOPO vectors and transformed into Escherichia coli TOP10 (Invitrogen, Darmstadt, Germany). Plasmids were isolated from selected clones and the inserted sequences were subjected to nucleotide sequencing to verify that no mutations had been introduced during the PCR and cloning procedures. E. coli ATCC 25922 was used as a control for the broth microdilution assay.
Bacterial strains used for MBL expression and purification were generated as described previously. 12 Briefly, genes encoding NDM-1, VIM-1, IMP-1 and SIM-1 MBLs were amplified by conventional PCR using the primers shown in Table S2 . The amplified DNA fragments were cleaved with respective restriction enzymes as given in Table S2 and then cloned into a correspondingly digested pET-24a expression vector. Competent E. coli BL21(DE3) cells were transformed with respective plasmids and transformants were selected on LB agar plates containing kanamycin (100 mg/L). Plasmids were isolated from selected clones and the inserted sequences were subjected to nucleotide sequencing to verify that no mutations had been introduced during PCR and cloning procedures.
MBL purification
E. coli clones harbouring the MBL plasmid were grown in 1 L of LB medium containing kanamycin (100 mg/L) at 37 C to an OD 600 of 0.8-1 before induction with 400 lM IPTG. Cells were allowed to grow for another 18-20 h at 21 C and harvested (10866 g, 20min, 4 C). Cell pellets were resuspended in 50 mL of buffer A (50 mM Tris/HCl pH 8, 500 mM NaCl, 5% glycerol, 20 mM imidazole/HCl pH 7) and supplemented with one EDTA-free protease inhibitor complete tablet (Roche, Basel, Switzerland) and a trace amount of DNase I (Applichem, Darmstadt, Germany) before passage through a cell disruptor (Constant Systems, Peterhead, UK) three times at 14500 psi. Broken cells were centrifuged for 60 min at 51632 g at 4 C to remove unbroken cells and cell debris. The supernatant was applied to a 5 mL HisTrap HP (GE Healthcare, Frankfurt, Germany) column, with buffer A as a running buffer and buffer B (50 mM Tris/HCl pH 8, 500 mM NaCl, 5% glycerol, 400 mM imidazole/HCl pH 7) as an elution buffer. The hexa-histagged MBL was purified using a step gradient protocol in which the protein of interest was eluted at an imidazole concentration of 115 mM. To remove imidazole, the fractions containing the MBL were pooled and concentrated by ultrafiltration through a CentriPrep concentrator (Merck Millipore, Billerica, MA, USA) with a 3 kDa membrane cut-off. The concentrated protein sample was loaded onto a Superdex 200 HiLoad 16/600 column (GE Healthcare, Frankfurt, Germany) equilibrated and run at 1 mL/min with buffer C (50 mM Tris/HCl pH 8, 500 mM NaCl, 5% glycerol). Protein concentrations were determined by NanoDrop (Thermo Fisher, Waltham, MA, USA), and the purity and identity of the MBLs (.95%) were determined by SDS-PAGE. Purified proteins for the assays were aliquoted, flash frozen in liquid nitrogen and stored at #80 C.
Fluorescence-based assay
Activity assays for MBLs were performed at room temperature in black polystyrol 96-well plates (Corning, Corning, NY, USA) using dicefalotinodifluorofluorescein (Fluorocillin, Invitrogen, Darmstadt, Germany) as a substrate. Proteins were diluted in assay buffer (HEPES 50 mM, pH 7.5 containing 0.01% Triton X-100), with final protein concentrations of (NDM-1) 3 nM, (VIM-1) 4 nM, (IMP-1) 1 nM and (SIM-1) 0.35 nM. Samples were supplemented with an equimolar amount of ZnCl 2 . An amount of 1 lL of EDDS (Sigma-Aldrich, Steinheim, Germany) at different concentrations was incubated with 89 lL of enzyme in assay buffer. After an incubation period of 30 min at room temperature, 10 lL of Fluorocillin substrate was added to yield the final assay volume of 100 lL. The fluorescence emitted by the fluorescent product difluorofluorescein was monitored every 45 s for 30 cycles using a Tecan fluorescent plate reader (Infinite 200; excitation at 495 nm and emission at 525 nm) and was compared with a standard curve. The rate of the enzymatic reaction was obtained by dividing the quantity of the fluorescent product (RFU) by time (min). Negative controls were measured in the absence of enzyme, whereas the positive controls were measured in the presence of enzyme and in the absence of inhibitors. The inhibitory effect of each substance was measured in triplicate in three independent experiments. IC 50 values were calculated using data obtained from measurements with at least six different inhibitor concentrations, applying a sigmoidal dose-response (variable slope with four parameters) equation using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) software. In order to investigate the inhibitory activity of EDDS in the presence of a high Zn 2! concentration, assay buffer containing an additional 100 lM ZnCl 2 was used. The assay was performed as described above with NDM-1 and either 30 or 100 lM EDDS.
Differential scanning fluorimetry (DSF)
DSF, also referred to as a thermal shift assay, 13 was performed in transparent 96-well PCR plates (MicroAmp, Applied Biosystems, Germany). The final assay volume was 40 lL. Test compounds EDDS and ZnCl 2 solution were dissolved in Milli-Q water and diluted in wells to a final concentration of 100 lM. Thirty-two microlitres of enzyme master mix containing assay buffer (50 mM HEPES, pH 7.8) and recombinant NDM-1 at a final concentration of 5 lM was mixed with 4lL of compound solution and 4 lL of SYPRO orange (Sigma-Aldrich) in assay buffer (2.5% final concentration). Melting points of untreated NDM-1 were measured without inhibitor. Temperaturedependent increase in fluorescence was measured from 25.0 C to 94.8 C, in steps of 0.2 C every 24 s, using an iCycler iQ single-colour real-time PCR (Bio-Rad, Munich, Germany). Excitation was set to 490 nm and emission wavelength to 570 nm. All measurements were performed in triplicate in three independent experiments. The first derivative of the melting curve was calculated using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). The respective maxima of the resulting curve, which were considered to be the melting point, were determined in Microsoft Excel.
Broth microdilution assay
MICs of piperacillin, cefuroxime, ceftazidime, imipenem monohydrate (all purchased from Sigma-Aldrich) and meropenem (Hikma, Graefeling, 14 Galleria mellonella infection model G. mellonella caterpillars infected with a lethal dosage of Klebsiella pneumoniae expressing NDM-1 were treated with imipenem + EDDS. Therefore, prior to inoculation into G. mellonella caterpillars, bacterial cells were washed with PBS and then diluted to an appropriate cell density, as determined by the optical density at 600 nm. A 10 lL Hamilton syringe was used to inject 10 lL aliquots of the inoculum into the haemocoel of each caterpillar via the last left proleg. Bacterial colony counts on blood agar were used to confirm the presence of inocula. Ten microlitres of imipenem + EDDS was then administered by injection into a different proleg within 30 min to yield a final concentration in the larvae of 0.4 mg/kg imipenem + 128 mg/kg EDDS. Sixteen randomly chosen caterpillars were used for each group of an experiment. For all experiments, two control groups were used: the first group included caterpillars that were inoculated with PBS to monitor for killing due to physical trauma; the second group included caterpillars that received no injection. Survival kinetics in terms of Kaplan-Meier plots were established to demonstrate differences between treated and untreated caterpillars over a timeframe of 4 days. Experiments were performed independently in triplicate and data were pooled.
Statistics
The log-rank (Mantel-Cox) test was used to compare survival curves by means of the software GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). P values ,0.05 were considered statistically significant.
Results
Purified recombinant NDM-1, VIM-1, SIM-1 and IMP-1 were used to analyse the inhibitory activity of EDDS in vitro (Figure 2a) (Figure 2b ). This assumption could be confirmed in the fluorescence-based activity assay, in which the addition of ZnCl 2 restored the activity of NDM-1 in the presence of EDDS.
The considerable inhibition of purified NDM-1, VIM-1 and SIM-1 in vitro suggested that EDDS can potentially restore the activity of b-lactam antibiotics against bacterial isolates producing MBL. To prove this, imipenem combined with different concentrations of EDDS ranging from 1 to 128 mg/L was tested against an E. coli mutant expressing NDM-1 (Table 1) . EDDS at a concentration of 8 mg/L already significantly reduced the MIC of imipenem for the MBL-expressing E. coli. Moreover, the addition of EDDS at a constant concentration of 32 mg/L reduced the MICs of all tested b-lactams for the E. coli mutant expressing NDM-1, whereas no synergistic effect of EDDS was observed for the MIC of gentamicin EDDS, a bacterial MBL inhibitor JAC (Table 2 ). The potentiating effect of EDDS against MBL-positive E. coli mutants is comparable to another chelator, i.e. EDTA, as shown in Table 3 . Finally, imipenem + EDDS at a constant concentration of 32 mg/L was tested against clinical isolates expressing various MBLs, i.e. NDM-1, NDM-5, NDM-7, IMP-1, IMP-7, VIM-1, VIM-2, VIM-4, SIM-1, SPM-1 and GIM-1, as well as carbapenemresistant MBL-negative Enterobacteriaceae and A. baumannii. The activity (MIC) of imipenem alone and in combination with EDDS is shown in Table 4 . EDDS did not exhibit any intrinsic antimicrobial activity at the tested constant concentration of 32 mg/L. However, combination of the MBL inhibitor and imipenem revealed that EDDS restored antibiotic activity, as demonstrated by a significant reduction in imipenem MICs for all tested MBL-positive but not MBL-negative isolates. The G. mellonella infection model demonstrated 100% killing of larvae infected with NDM-1-producing K. pneumoniae (Figure 3) . Treatment of infected G. mellonella with either EDDS or imipenem did not result in a significantly higher survival rate. However, treatment with EDDS ! imipenem resulted in a significantly higher survival rate of larvae inoculated with NDM-1-producing K. pneumoniae (Figure 3 ).
Discussion
Gram-negative bacteria such as Enterobacteriaceae, P. aeruginosa and A. baumannii are considered to be major nosocomial pathogens causing acute infections such as sepsis, pneumonia, urinary tract infections and skin and soft tissue infections. [15] [16] [17] Antibiotic therapy plays a crucial role in the management and cure of these infections in humans. The broad spectrum of antibiotic resistance associated with these versatile pathogens is worrying because antibiotic resistance in general increases the morbidity and mortality. [18] [19] [20] [21] The spread of carbapenemases among these pathogens, which can confer resistance to almost all b-lactams, including carbapenems, is especially alarming. 2 This study aimed to provide a new anti-infective b-lactam/ b-lactamase inhibitor combination, i.e. imipenem/EDDS, to combat infections in humans due to MBL-producing pathogens.
EDDS showed potent concentration-dependent inhibition of purified NDM-1, VIM-1 and SIM-1. These results are in agreement with the broth microdilution assays. EDDS affected the imipenem MIC for NDM-1-expressing transformants (512-fold) more strongly than the imipenem MIC for VIM-1-and SIM-1-expressing transformants (8-and 16-fold, respectively) at concentrations slightly higher than 100 lM. These results correspond to the findings by King et al., 10 showing that aspergillomarasmine A potently inhibited NDM-1 whereas the inhibition of related MBLs VIM-2 and IMP-7 was less pronounced. IMP-1 was almost unaffected by EDDS in concentrations up to 300 lM. The experiments performed by Laraki et al. 22 also show that IMP-1 is only weakly affected by EDTA. Different susceptibility of the investigated MBLs to EDDS might be explained by structural differences between these enzymes. There is a large difference in the flexibility of loops surrounding the active site in NDM-1 compared with MBLs of the VIM and IMP family. 23 Furthermore, the binding cavity is wider, 24, 25 which enables more efficient catalysis and a broader substrate spectrum, 26 and it might also have an impact on the binding affinity of zinc ions to the catalytic site. One might speculate that MBLs with low binding affinity to zinc ions are more susceptible to 
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inhibition by zinc chelators like EDTA, EDDS and aspergillomarasmine A; however, this hypothesis has to be verified experimentally. With regard to clinical isolates, EDDS significantly reduced the imipenem MIC for all MBL-expressing bacteria under investigation, with the most pronounced effect, i.e. up to 512-fold imipenem MIC reduction, for bacteria expressing the clinically relevant NDM.
The activity of the synthetic chelator Ca-EDTA in combination with ceftazidime or imipenem against MBL-producing bacteria has been analysed in vitro as well as in vivo and favourable results could be achieved. 27, 28 Ca-EDTA is widely used in clinics for the treatment of lead intoxication and is applied intravenously in doses between 25 and 75 mg/kg/day. 27 EDDS might be applicable intravenously as well and in vivo pharmacokinetic studies need to be performed. 29 EDDS is produced by bacteria as a natural compound that is biodegradable. As such, it offers an advantage over the poorly biodegradable EDTA, which cannot be removed by conventional water treatments, thereby exerting a constant environmental stress. 22 In conclusion, we demonstrated that the bacterial zincophore EDDS is a highly efficient inhibitor of MBL. In combination with imipenem, EDDS demonstrated excellent activity against various MBL-producing Gram-negative pathogens in vitro as well as in vivo. Further investigation of EDDS as a chelating agent against infections due to MBL-producing pathogens, including animal studies, is warranted. Furthermore, to the best of our knowledge, EDDS is the first MBL inhibitor of bacterial origin. Although EDDS is described as a zincophore, its role in interspecies competition is unclear and should be further investigated. Figure 3 . Survival curves of G. mellonella larvae infected with NDM-1-producing K. pneumoniae and treated with imipenem, EDDS or imipenem ! EDDS. Curves represent pooled data from three independent experiments using 16 G. mellonella in each experiment. *P , 0.0001. IPM, imipenem; K.p., K. pneumoniae.
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